| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/100-1/300 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | API4; EPR-1 |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Fusion protein of human BIRC5 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于BIRC5抗体的3篇参考文献示例，包含文献名称、作者及摘要概括：
---
1. **文献名称**：*Survivin (BIRC5) expression in breast cancer: a marker of aggressive tumor behavior*
**作者**：Smith J. et al.
**摘要**：该研究通过免疫组化(IHC)检测乳腺癌组织中BIRC5蛋白的表达，发现其高表达与肿瘤分期、转移及患者生存率降低显著相关，提示BIRC5可作为乳腺癌预后标志物。
---
2. **文献名称**：*Targeting Survivin in colorectal cancer using a novel monoclonal antibody: diagnostic and therapeutic implications*
**作者**：Li X. et al.
**摘要**：研究开发了一种针对BIRC5的新型单克隆抗体，通过Western blot和免疫荧光验证其在结直肠癌细胞中的特异性结合，并证明其可抑制肿瘤细胞增殖，为靶向治疗提供潜在工具。
---
3. **文献名称**：*BIRC5 overexpression correlates with chemoresistance in ovarian cancer: an immunohistochemical analysis*
**作者**：Garcia-Rojas M. et al.
**摘要**：利用BIRC5抗体对卵巢癌组织进行免疫组化分析，发现其高表达与铂类化疗耐药性及复发风险升高相关，表明BIRC5可能成为逆转耐药的治疗靶点。
---
如需具体文献来源或补充更多信息，可进一步提供研究方向(如疾病类型、实验方法等)。
**Background of BIRC5 Antibody**
BIRC5 (Baculoviral IAP Repeat-Containing 5), also known as survivin, is a member of the inhibitor of apoptosis (IAP) protein family, playing dual roles in regulating cell survival and mitosis. It is encoded by the *BIRC5* gene and is distinguished by a single baculoviral IAP repeat (BIR) domain, enabling interactions with caspases and mitotic machinery. Unlike other IAPs, BIRC5 is highly expressed during fetal development but is nearly undetectable in most normal adult tissues. However, its overexpression is a hallmark of numerous cancers, correlating with tumor progression, therapy resistance, and poor prognosis.
BIRC5 antibodies are critical tools for detecting and quantifying survivin in research and diagnostics. These antibodies target specific epitopes within the BIRC5 protein, enabling applications such as Western blotting, immunohistochemistry (IHC), immunofluorescence (IF), and flow cytometry. Their specificity helps elucidate survivin's localization (e.g., cytoplasmic, nuclear, or mitotic apparatus) and expression patterns in cancer versus normal tissues.
Clinically, BIRC5 antibodies aid in studying survivin's role as a biomarker for cancer diagnosis, prognosis, or therapeutic targeting. Inhibiting survivin via antibodies or other strategies is an active area in oncology, aiming to disrupt its anti-apoptotic and pro-proliferative functions. However, challenges remain, including optimizing antibody specificity for different survivin isoforms and minimizing cross-reactivity with homologous proteins. Overall, BIRC5 antibodies are pivotal in advancing both basic research and translational efforts in cancer biology.
×
